References of "Gharbi, Myriam"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailFibulin 3 peptides Fib3-1 and Fib3-2 are potential biomarkers of osteoarthritis.
Henrotin, Yves ULg; Gharbi, Myriam; Mazzucchelli, Gabriel ULg et al

in Arthritis and Rheumatism (2012), 64(7), 2260-7

OBJECTIVE: This study was undertaken to identify new biomarkers of osteoarthritis (OA) by proteomics analysis and to develop specific immunoassays to detect and quantify them. METHODS: Proteomics analysis ... [more ▼]

OBJECTIVE: This study was undertaken to identify new biomarkers of osteoarthritis (OA) by proteomics analysis and to develop specific immunoassays to detect and quantify them. METHODS: Proteomics analysis was performed in urine samples from 10 women (mean+/-SD age 76.0+/-5.0 years) undergoing knee replacement surgery due to severe OA and 5 healthy women (mean+/-SD age 25.6+/-2.6 years). Protein content was analyzed by 2-dimensional differential gel electrophoresis. Protein spots that exhibited an OA:control abundance ratio of >/=1.5 were identified by mass spectrometry. Specific enzyme-linked immunosorbent assays were developed and validated in serum obtained from 236 healthy subjects ages 20-64 years and from 76 patients with severe radiologic knee OA (mean+/-SD age 68.8+/-11.9 years). Immunohistochemical analysis was performed on articular cartilage from tibial plateaus. RESULTS: Thirteen proteins within spots that were significantly modified between groups were identified. Two peptides of fibulin 3, named Fib3-1 and Fib3-2, were of particular interest. Two antisera directed against these peptides were used to develop immunoassays. Compared with age-matched healthy subjects, median levels of serum Fib3-1 and Fib3-2 were elevated in OA patients (54.6 pM versus 85.1 pM [P<0.0001] and 144.4 pM versus 191.4 pM [P<0.0001], respectively). Using area under the receiver operating characteristic curve analysis, we demonstrated that Fib3-1 and Fib3-2 levels discriminate between OA and normal populations. Immunostaining revealed the presence of Fib3-1 and Fib3-2 in chondrocytes and in the extracellular matrix of the superficial layer of the fibrillated cartilage. CONCLUSION: Our findings indicate that Fib3-1 and Fib3-2 are potential biochemical markers for the diagnosis of OA. [less ▲]

Detailed reference viewed: 16 (4 ULg)
Full Text
See detailBIOMARKER FOR OSTEOARTHRITIS AND/OR OTHER AGEING-RELATED DISEASES, AND USE THEREOF
Henrotin, Yves ULg; Gharbi, Myriam; Deberg, Michelle et al

Patent (2011)

The invention relates to the identification of abiomarker whose abundance in biological sampleis changed in subjects with osteoarthritis and/or other ageing-related diseases. Thebiomarker hasapplications ... [more ▼]

The invention relates to the identification of abiomarker whose abundance in biological sampleis changed in subjects with osteoarthritis and/or other ageing-related diseases. Thebiomarker hasapplications in the diagnosis of osteoarthritis and/or other ageing-related diseases, in determining the prognosis for an individual diagnosed with osteoarthritis and/or other ageing-related diseases, and in monitoring the efficacy of treatment for osteoarthritis and/or other ageing-related diseases. [less ▲]

Detailed reference viewed: 11 (5 ULg)
Full Text
See detailBIOMARKER FOR OSTEOARTHRITIS AND/OR OTHER AGEING-RELATED DISEASES, AND USE THEREOF
Henrotin, Yves ULg; Gharbi, Myriam; Deberg, Michelle et al

Patent (2011)

The invention relates to the identification of abiomarker whose abundance in biological sampleis changed in subjects with osteoarthritis and/or other ageing-related diseases. Thebiomarker hasapplications ... [more ▼]

The invention relates to the identification of abiomarker whose abundance in biological sampleis changed in subjects with osteoarthritis and/or other ageing-related diseases. Thebiomarker hasapplications in the diagnosis of osteoarthritis and/or other ageing-related diseases, in determining the prognosis for an individual diagnosed with osteoarthritis and/or other ageing-related diseases, and in monitoring the efficacy of treatment for osteoarthritis and/or other ageing-related diseases. [less ▲]

Detailed reference viewed: 10 (3 ULg)
Full Text
Peer Reviewed
See detailL’interleukine-1β augmente le catabolisme de la fibuline-3 par les chondrocytes : démonstration in vitro par la mesure des fragments Fib3-1 et Fib3-2
Gharbi, Myriam; Legrand, Catherine; Sanchez, Christelle ULg et al

in Revue du Rhumatisme (2011), 78(suppl 5), 131-132

Detailed reference viewed: 26 (8 ULg)
Full Text
Peer Reviewed
See detailApplication for proteomic techniques in studying osteoarthritis: a review
Gharbi, Myriam; Deberg, Michelle ULg; Henrotin, Yves ULg

in Frontiers in Physiology (2011), 2(90), 1-11

Detailed reference viewed: 15 (5 ULg)
Full Text
See detailBiomarker for osteoarthritis and/or other ageing-related diseases, and use thereof
Henrotin, Yves ULg; Gharbi, Myriam; Deberg, Michelle et al

Patent (2009)

The invention relates to the identification of a biomarker whose abundance in bodily fluids is changed in subjects with osteoarthritis and/or other ageing-related diseases. The biomarker has applications ... [more ▼]

The invention relates to the identification of a biomarker whose abundance in bodily fluids is changed in subjects with osteoarthritis and/or other ageing-related diseases. The biomarker has applications in the diagnosis of osteoarthritis and/or other ageing-related diseases, in determining the prognosis for an individual diagnosed with osteoarthritis and/or other ageing-related diseases, and in monitoring the efficacy of treatment for osteoarthritis and/or other ageing-related diseases. [less ▲]

Detailed reference viewed: 10 (4 ULg)